New drug combo aims to boost immune system against lung cancer in bones
NCT ID NCT06738160
Summary
This study is testing if adding two treatments—a drug called narlumosbart and precise radiation therapy—to standard first-line chemo-immunotherapy can improve results for people with advanced non-small cell lung cancer that has spread to their bones. The goal is to see if this combination helps shrink tumors and control the cancer for longer. It is for adults with this type of lung cancer who have not yet started any drug treatment for it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.